2002-03-08-世界卫生组织-INN_Proposed_List_86_44页_262kb

报告摘要

Summary of Proposed and Recommended International Nonproprietary Names (INN)

Core Content

The document outlines the process and content of the International Nonproprietary Names for Pharmaceutical Substances (INN), a system used to assign unique names to pharmaceutical substances. It provides information on Proposed INNs and Recommended INNs, along with their chemical names, properties, and uses. The names are presented in multiple languages: Latin, English, French, and Spanish, reflecting the international nature of the system. The document also includes molecular formulas, CAS registry numbers, and graphic formulas for the listed substances.

Main Points

Purpose of INN:
The INN system is designed to provide standardized, non-proprietary names for pharmaceutical substances to ensure clarity and consistency in global communication.
Provisional Nature of Proposed INNs:
- Proposed names are under consideration by the World Health Organization (WHO).
- Inclusion in the Proposed list does not imply recommendation for medical or pharmaceutical use.
- These names are not revised and not included in the Cumulative Lists of INNs.
Submission of Comments or Objections:
- Any person may submit comments or formal objections to proposed names within four months of publication in WHO Drug Information.
- For List 86, the deadline was 31 October 2002.
Structure of the Document:
- Each entry includes the Proposed INN, Chemical name, Action and use, Molecular formula, CAS registry number, and Graphic formula.
- The names are presented in Latin, English, French, and Spanish for international recognition and use.

Key Information

List 86 includes several proposed names, such as acolbifenum, bazedoxifenum, deferasiroxum, degarelixum, lubazodonum, naxifyllinum, otamixabanum, and paliferminum.
Each substance is described with its chemical name, properties, indication, and molecular data.
The chemical names are detailed, with Latin, English, French, and Spanish variations.
The molecular formulas and CAS numbers are provided for each substance to facilitate identification and use in scientific and pharmaceutical contexts.
Graphic formulas are included for visual representation of the chemical structures.
The properties and use of each substance are based on manufacturer information, but WHO does not confirm or comment on their efficacy.

Examples of Substances

Proposed INN	Chemical Name	Action and Use	Molecular Formula	CAS Registry Number
acolbifenum	(+)-(2S)-3-(4-hydroxyphenyl)-4-methyl-2-[4-[2-(piperidin-1-yl)ethoxy]phenyl]-2H-1-benzopyran-7-ol	antiestrogen	C29H31NO4	182167-02-8
bazedoxifenum	1-[4-[2-(hexahydro-1H-azepin-1-yl)ethoxy]benzyl]-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol	antiestrogen	C31H35ClN2O3	198481-32-2
deferasiroxum	4-[3,5-bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]benzoic acid	chelating agent	C28H35NO4	201530-41-8
degarelixum	N-acetyl-3-(naphtalen-2-yl)-D-alanyl-4-chloro-D-phenylalanyl-3-(pyridin-3-yl)-D-alanyl-L-seryl-4-[[(4S)-2,6-dioxohexahydropyrimidin-4-yl]carbonyl]amino]-L-phenylalanyl-4-(carbamoylamino)-D-phenylalanyl-L-leucyl- $N^6$ -(1-methylethyl)-L-lysyl-L-prolyl-D-alaninamide	gonadotropin-releasing hormone antagonist	C82H103ClN18O16S10	214766-78-6
lubazodonum	(2S)-2-[[(7-fluoro-2,3-dihydro-1H-inden-4-yl)oxy]methyl]morpholine	antidepressant	C14H18FN2O2	161178-07-0
naxifyllinum	8-[(1S,2R,4S,5S,6S)-3-oxatricyclo[3.2.1.02.4]oct-6-yl]-1,3-dipropyl-3,7-dihydro-1H-purine-2,6-dione	adenosine receptor antagonist	C18H24N4O3	166374-49-8
otamixabanum	methyl (2R,3R)-2-(3-carbamimidoylbenzyl)-3-[[4-(1-oxidopyridin-4-yl)benzoyl]amino]butanoate	blood-coagulation factor Xa inhibitor	C25H26N4O4	193153-04-7
paliferminum	[23-methionine]-23-163-fibroblast growth factor 7 (human clone 32/49 reduced)	fibroblast growth factor	C729H1156N204O207S10	-
peramivirum	(1S,2S,3R,4R)-3-[(1S)-1-(acetylamino)-2-ethylbutyl]-4-(carbamimidoylamino)-2-hydroxycyclopentanecarboxylic acid	antiviral	C15H28N4O4	229614-55-5
talibegronum	[4-[2-[[(2R)-2-hydroxy-2-phenylethyl]amino]ethoxy]phenyl]acetic acid	β3-adrenoreceptor agonist	C18H21NO4	146376-58-1
tariquidarum	N-[2-[[4-2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl]phenyl]carbamoyl]-4,5-dimethoxyphenyl]quinoline 3-carboxamide	multidrug resistant inhibitor, antineoplastic	C26H27N5O6	206873-63-4
tebaniclinum	5-[(2R)-azetidin-2-ylmethoxy]-2-chloropyridine	analgesic, nicotinic acetylcholine receptor agonist	C9H11CIN2O	198283-73-7
tecastemizolum	1-(4-fluorobenzyl)-N-(piperidin-4-yl)-1H-benzimidazol-2-amine	antihistaminic	C19H21FN4	75970-99-9
technetium (99mTc) fanolesomabum	immunoglobulin M, anti-(human CD15 antigen) (mouse monoclonal RB5 μ-chain), disulfide with mouse monoclonal RB5 light chain, pentamer	immunomodulator, radiodiagnostic agent	C225H325N50S10	225239-31-6

Conclusion

The document serves as a reference for the proposed and recommended names of pharmaceutical substances by the World Health Organization (WHO), emphasizing the international standardization of drug names. It outlines the provisional nature of proposed names and the importance of standardized naming in the pharmaceutical industry. The multilingual approach (Latin, English, French, Spanish) and the inclusion of chemical information ensure that the names are accessible and usable globally. The submission period for feedback is clearly defined, allowing for public input on the proposed names.

展开完整摘要